- Method for producing tetrabromobisphenol A diglycidyl ether
-
The invention discloses a method for producing tetrabromobisphenol A diglycidyl ether. The method comprises the following synthesis steps: tetrabromobisphenol A and excessive epichlorohydrin are thrown into a reaction vessel and heated to 50-70 DEG C, an aqueous solution of an initiator is added dropwisely, and a reaction is carried out for 4-5 hours; the aqueous solution of the initiator is added dropwisely in a vacuum condition again, in the process of the reaction, epichlorohydrin is dewatered by distillation for backflow to the reaction vessel, the reaction is continuous to carry out for 4-5 hours, reduced pressure distillation is carried out in order to obtain unreacted epichlorohydrin, nitrogen is filled for removing vacuum, water and methyl isobutyl ketone are added, an aqueous phase is discharged by extraction, an organic phase is distilled at 110-120 DEG C, filtering is carried out while hot, filtrate is transferred to a crystallization kettle, crystallization is carried out at 0-35 DEG C, after crystallization, centrifugal filtering is carried out in order to obtain precipitation, the precipitation is transferred to the reaction vessel for carrying out reduced pressure distillation, a colorless transparent organic matter is obtained, and cooling solidification, crushing and package are carried out. The method substantially reduces energy consumption and reduces production cost, at the same time the product fills the domestic blank, and international environmental protection requirements are achieved.
- -
-
Paragraph 0014; 0015
(2017/01/02)
-
- Structural optimization and biological evaluation of substituted bisphenol a derivatives as β-amyloid peptide aggregation inhibitors
-
The aggregation of A? is a crucial step in the etiology of Alzheimer's disease. Our previous work showed that A? undergoes ?-helix/?-sheet intermediate structures during the conformational transition, and an A? aggregation inhibitor (1) was discovered by targeting the intermediates. Here, structure optimization toward compound 1 was performed and 34 novel derivatives were designed and synthesized. Nine compounds showed more effective inhibitory activity than the hit compound 1 in ThT fluorescence assay. Among them, compound 43 demonstrated more excellent inhibitory potency, which not only can suppress the aggregation of A? but also can dissolve the preformed fibrils as shown by CD spectroscopy, PICUP and AFM assays. Cellular assay indicated that 43 has no toxicity to neuronal cells, moreover, can effectively inhibit A? 1?42-induced neutrotoxicity and increase the cell viability. Together, on the basis of these positive results, these novel chemical structures may provide a promising potential for therapeutic applications in AD and other types of neurodegenerative disorders.
- Zhou, Yu,Jiang, Chunyi,Zhang, Yaping,Liang, Zhongjie,Liu, Wenfeng,Wang, Liefeng,Luo, Cheng,Zhong, Tingting,Sun, Yi,Zhao, Linxiang,Xie, Xin,Jiang, Hualiang,Zhou, Naiming,Liu, Dongxiang,Liu, Hong
-
experimental part
p. 5449 - 5466
(2010/11/05)
-
- PROCESS FOR EPOXIDATION OF ARYL ALLYL ETHERS
-
A process for making an aromatic glycidyl ether epoxy compound by contacting an allyl ether made from the hydroxy moiety of a hydroxy-containing aromatic compound with an inorganic or organic hydroperoxide oxidant in the presence of a transition metal complex catalyst, wherein at least (a) the allyl ether is conformationally restricted or (b) the transition metal complex catalyst contains at least one or more stable ligands attached to the transition metal. The process of the present invention provides for epoxidizing aryl allyl ethers with high epoxidation yield (for example, greater than 70 percent to 90 percent) and high hydroperoxide selectivity (for example, greater than 70 percent to 90 percent).
- -
-
-